Risk of Motor Complications in Early Parkinson’s Disease Patients Treated with Opicapone in the EPSILON study: Effect of Levodopa Dose
Objective: This post-hoc analysis of the EPSILON study evaluated whether levodopa dose (<400mg/day vs. ≥400mg/day) and opicapone (OPC) timing (at double-blind [DB] or open-label extension…Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis
Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…The efficacy and safety of continuous subcutaneous infusion therapy with foslevodopa/foscarbidopa
Objective: To clarify the actual status of CSCI therapy, cases in which CSCI therapy was started at our hospital were investigated. Background: Continuous subcutaneous infusion…Effect of Opicapone on Sleep-Related Complaints and Non-Motor Burden in Parkinson’s Patients: A Post-Hoc Analysis of the OASIS Trial
Objective: To assess the effect of opicapone (OPC) on different sleep complaints and non-motor symptoms (NMS) in fluctuating Parkinson’s disease (PD) patients with sleep disturbances.…Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis
Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…Levodopa response in pathology-confirmed Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy
Objective: to describe the rate of levodopa response, phenotypical characteristics, prognostic implications and pathological features in a large cohort of patients with pathology-confirmed Parkinson’s disease…Nocturnal Use of Add-On Medications for Parkinson’s Disease: Post Hoc Analysis of the COSMOS Study
Objective: To assess nighttime use of add-on medications for Parkinson’s disease (PD) in a post hoc analysis of the COSMOS (COmedication Study assessing Mono- and…Pre-treatment with Methanolic Extract Mucuna pruriens Seeds Attenuates Serotonin Gene Depletion, Motor Dysfunction and Anxiogenic Responses in a Rat Model of Parkinsonism
Objective: Investigate neuroprotective and genoprotective effects of methanolic Mucuna pruriens (Mp) seed extract in a paraquat-induced Parkinsonism rat model. Background: Paraquat exposure has been linked…Digital health technology (DHT) derived features as sensitive measures of disease progression in early Parkinson’s disease under stable dopaminergic treatment
Objective: To evaluate the ability of DHT derived features from remotely collected active tests to measure disease progression in individuals with early Parkinson’s disease (PD)…Effect of Istradefylline on Motor and Non-motor Symptoms in Patients with Parkinson’s Disease: the ISTRA ADJUST PD Randomized, Controlled Study
Objective: To examine the effects of istradefylline on motor and non-motor symptoms in Parkinson’s disease (PD) patients with wearing-off phenomena. Background: Previous results [1,2] of…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 70
- Next Page »